Active, not recruitingPhase 3NCT04543591

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Studying Thrombotic microangiopathy

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Alexion Pharmaceuticals, Inc.
Intervention: Ravulizumab(biological)
Enrollment: 148 target
Eligibility: 12-100 years · All sexes
Timeline: 2020 – 2026

Study locations (30)

Research Site, Tampa, Florida, United States
Research Site, Grosse Pointe Farms, Michigan, United States
Research Site, Durham, North Carolina, United States
Research Site, Pittsburgh, Pennsylvania, United States
Research Site, Seattle, Washington, United States
Research Site, Parkville, Australia
Research Site, Bruges, Belgium
Research Site, Brussels, Belgium
Research Site, Chênée, Belgium
Research Site, Yvoir, Belgium
Research Site, Cerqueira César, Brazil
Research Site, Florianópolis, Brazil
Research Site, Jaú, Brazil
Research Site, Porto Alegre, Brazil
Research Site, Rio de Janeiro, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04543591 on ClinicalTrials.gov

Other trials for Thrombotic microangiopathy

Additional recruiting or active studies for the same condition.

See all trials for Thrombotic microangiopathy →

← Back to all trials